About
Oxford Nanopore Technologies (ONT) provides a comprehensive nanopore sequencing platform that is transforming genomics research across academia, clinical research, and industry. Unlike traditional short-read sequencing, ONT's technology generates short to ultra-long native DNA and RNA reads in real time — without requiring PCR amplification or chemical conversion — enabling richer biological insights including epigenetic modifications, structural variants, and full-length transcripts. The platform spans three layers: library preparation solutions that fast-track workflows in minutes; a range of sequencing devices from the pocket-sized MinION to high-throughput benchtop systems; and EPI2ME, a software and informatics suite offering preconfigured analysis workflows and cutting-edge bioinformatics tools. AI and machine learning are deeply embedded in base-calling and variant detection, continuously improving accuracy. Applications span microbial genomics, human genomics, cancer research, metagenomics, transcriptomics, infectious disease surveillance, environmental conservation, and clinical diagnostics. ONT's scalable, near-sample, real-time sequencing removes traditional batching bottlenecks, making genomic insights accessible in the field, clinic, or lab. The platform supports researchers, clinical scientists, biopharma organizations, and public health agencies worldwide, having been used for over 20 years to drive global genomic discovery.
Key Features
- Ultra-Long Native Read Sequencing: Generates short to ultra-long native DNA and RNA reads without PCR amplification, preserving epigenetic information and enabling detection of structural variants and full-length transcripts.
- Real-Time Analysis with EPI2ME: EPI2ME provides preconfigured workflows and advanced bioinformatics tools that analyze sequencing data in real time, eliminating the need for batching and accelerating results.
- Scalable Device Ecosystem: A range of devices from the palm-sized MinION to high-throughput benchtop sequencers accommodates every use case, from field deployments to large-scale population genomics.
- AI-Powered Base Calling & Variant Detection: Machine learning models continuously improve base-calling accuracy and enable highly accurate detection of SNVs, epigenetic marks, structural variations, and splice variants.
- Comprehensive Library Preparation Solutions: Streamlined, cost-effective library prep kits and automation solutions support rapid workflow setup across a broad range of sample types and sequencing applications.
Use Cases
- Real-time infectious disease surveillance and outbreak monitoring in the field using portable MinION devices
- Whole-genome sequencing and assembly of complex genomes with ultra-long reads for improved contiguity and phasing
- Simultaneous detection of genetic variants and epigenetic modifications in cancer research without separate assays
- Environmental metagenomics to characterize microbial communities in soil, water, or host microbiomes
- Clinical research into hereditary cancers using the Oxford Nanopore Hereditary Cancer Panel for combined genomic and epigenomic insights
Pros
- Unmatched Read Length Flexibility: The ability to generate ultra-long reads (hundreds of kilobases) provides superior genome assembly, phasing, and structural variant detection compared to short-read platforms.
- Native DNA & Epigenetic Detection: Sequences native DNA without bisulfite conversion, simultaneously capturing base sequence and methylation status in a single run.
- Portable and Deployable: The MinION device weighs under 100g, enabling real-time sequencing in remote field sites, point-of-care settings, and resource-limited environments.
- Broad Application Coverage: Supports an extensive range of applications — from metagenomics and transcriptomics to cancer genomics and infectious disease surveillance — with validated, ready-to-use workflows.
Cons
- Significant Hardware Investment Required: Full utilization of the platform requires purchasing proprietary sequencing devices and consumables, representing a high upfront cost for new labs.
- Steep Bioinformatics Learning Curve: Analyzing long-read nanopore data requires familiarity with specialized bioinformatics tools and pipelines that differ substantially from short-read workflows.
- Higher Raw Error Rate vs. Short-Read Platforms: Although accuracy has improved dramatically with AI-based base callers, raw per-read error rates can still be higher than Illumina short-read sequencing for certain applications.
Frequently Asked Questions
What makes Oxford Nanopore sequencing different from traditional sequencing methods?
Oxford Nanopore sequencing passes native DNA or RNA molecules through a protein nanopore and measures the electrical current changes to identify bases in real time. This allows ultra-long reads, native epigenetic detection, and on-device real-time analysis — capabilities not available with short-read sequencing platforms like Illumina.
What devices does Oxford Nanopore offer?
ONT offers a range of sequencing devices to suit different throughput needs, including the portable MinION, the benchtop GridION and PromethION for high-throughput applications, and specialized devices for clinical and field use.
What software tools are available for data analysis?
Oxford Nanopore provides EPI2ME, a cloud and desktop platform offering preconfigured analysis workflows for common applications. They also support a range of open-source community tools and provide APIs for custom bioinformatics pipeline development.
Which research applications is Oxford Nanopore sequencing suited for?
The platform supports a broad spectrum of applications including whole-genome sequencing, transcriptomics, epigenetics, metagenomics, cancer genomics, infectious disease surveillance, structural variation analysis, single-cell sequencing, and environmental genomics.
Is Oxford Nanopore sequencing suitable for clinical use?
Oxford Nanopore supports clinical research applications and has developed specific panels such as the Hereditary Cancer Panel. Regulatory approval status varies by region and intended use; users should verify compliance requirements for their specific clinical context.
